News Releases

Year

02 Jun '21

Repare Therapeutics to Participate at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Jun. 2, 2021-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today

13 May '21

Repare Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results

Introduced PKMYT1 as synthetic-lethal target for tumors with CCNE1 amplification or FBXW7 loss and highlighted program progress at RP-6306 Virtual Investor Day Event Announced enrollment of first patient in RP-6306 Phase 1 clinical trial Activated 10 clinical trial sites across North America and

03 May '21

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--May 3, 2021-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality (SL) approach to the discovery and development of novel therapeutics,

13 Apr '21

Repare Therapeutics to Present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference

CAMBRIDGE, Mass. & MONTREAL, Quebec --(BUSINESS WIRE)--Apr. 13, 2021-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel

08 Apr '21

Repare Therapeutics to Highlight Program Progress for RP-6306 at Today’s Virtual Investor Day Event

-Company highlights pre-clinical anti-tumor activity of RP-6306 , a first-in-class, selective, oral inhibitor of PKMYT1, which is synthetic lethal with CCNE1 amplification and other genomic mutations- - Initiation of Phase 1 clinical trial enrollment for RP-6306 anticipated to begin during this

30 Mar '21

Repare Therapeutics to Introduce RP-6306, a Potent and Specific Inhibitor of a Novel Target, at Virtual Investor Day on April 8

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Mar. 30, 2021-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics,

29 Mar '21

Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Mar. 29, 2021-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics,

04 Mar '21

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Initiated patient recruitment of PARP-inhibitor combination arm of RP-3500 TRESR Phase 1/2 clinical trial Initiated IND-enabling studies for RP-6306 , the Company’s CCNE-1 synthetic-lethal inhibitor program Phase 1 clinical trial for RP-6306 is anticipated to commence in 2Q 2021, reflecting a

23 Feb '21

Repare Therapeutics Announces March 2021 Virtual Investor Conference Participation

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Feb. 23, 2021-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics,

04 Jan '21

Repare Therapeutics to Present at Virtual Investor Conferences in January

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Jan. 4, 2021-- Repare Therapeutics, Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics,